# D2M

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/d2m

- Industry: Biotechnology
- Headquarters: Suzhou, China
- Total disclosed funding: $20M
- Latest round: Series A (Dec 26, 2022)
- Investors on record: 2

## About

Based in Suzhou, China, and established in 2020, D2M is a biopharmaceutical company that engages in the R&D of new drugs for tumors and autoimmune diseases. The company was co-established by Dr. Nan Bing and Dr. Dong Zhang. Dr. Nan Bing worked at Pfizer as a director of human genetics targeting. And Dr. Dong Zhang worked at Merck as a director of tumor immunity. In April 2023, the company raised a strategic investment from new investors. 

D2M engages in the R&D of new drugs for tumors and autoimmune diseases. It self-developed genetics-centric and multi-omics integrated data targets discovery platforms, which discovered and verified new drug targets based on the genome-wide association study data of human diseases, integrated multi-omics data, and application of mendelian randomization simulation random trials. 

The company will use the strategic investment raised in April 2023 to advance the clinical filings of two large molecule programs and the iterative upgrade of the GAMID® target discovery platform.

## Funding rounds

- Series A, Dec 26, 2022, $20M — Delian Capital, Lapam Capital

## Investors

- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series A
- Lapam Capital (https://capitalatlas.ai/funds/lapam-capital) — Series A